Last week, Italian pharmaceutical company Fidia Farmaceutici (Fidia) announced their acquisition of 100% of the share capital of Altacor Ltd. Buying up the UK-based company specializing in ocular surface disease and ophthalmic surgery marks a significant milestone for Fidia, which is slowly expanding its operational footprint and multinational reach into the ophthalmology industry and other healthcare sectors.
Altacor’s own growing portfolio includes Clinitas, preservative-free eye drops and gels manufactured by the company for dry eye treatment. The acquisition will allow Fidia to make commercial use of existing products like Clinitas, while also introducing their own products and treatments into the UK market. Currently, these products include a wide range of artificial tears formulated with Fidia’s patented “Fidia Hyaluronic Acid (FHA 1.0),” drops and gels that are made up of 0.15% hyaluronic acid and a carefully balanced combination of amino acids.
Speaking of Fidia’s long-term investment plans, the President and CEO of the company, Carlo Pizzocaro, says, “Building on a series of strategic M&A operations completed in recent years, the acquisition of Altacor represents another milestone in our international growth journey. We are increasingly focusing our investments on high-potential markets, such as the UK, to strengthen our global presence and expand into new therapeutic areas. By broadening our product portfolio and gaining access to complementary channels, we will further reinforce our position as a leading international player, delivering innovative and effective solutions to meet patient needs in every country where we operate”.
Source: Pharmiweb.com.
Altacor’s own growing portfolio includes Clinitas, preservative-free eye drops and gels manufactured by the company for dry eye treatment. The acquisition will allow Fidia to make commercial use of existing products like Clinitas, while also introducing their own products and treatments into the UK market. Currently, these products include a wide range of artificial tears formulated with Fidia’s patented “Fidia Hyaluronic Acid (FHA 1.0),” drops and gels that are made up of 0.15% hyaluronic acid and a carefully balanced combination of amino acids.
Speaking of Fidia’s long-term investment plans, the President and CEO of the company, Carlo Pizzocaro, says, “Building on a series of strategic M&A operations completed in recent years, the acquisition of Altacor represents another milestone in our international growth journey. We are increasingly focusing our investments on high-potential markets, such as the UK, to strengthen our global presence and expand into new therapeutic areas. By broadening our product portfolio and gaining access to complementary channels, we will further reinforce our position as a leading international player, delivering innovative and effective solutions to meet patient needs in every country where we operate”.
Source: Pharmiweb.com.
